Dalpiciclib

Generic Name: Dalpiciclib

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₂₅H_₃₀N_₆O_₂

CAS Number: 1637781-04-4

Unique Ingredient Identifier: 5ZHA5P4PFX

Associated Conditions: -

Associated Therapies: -

Clinical Trials

Dalpiciclib, Fulvestrant, Trastuzumab and Pertuzumab in HR Positive, HER2 Positive Metastatic Breast Cancer

Phase 1

Active, not recruiting

Conditions: Breast Cancer

Interventions: Drug: Dalpiciclib
Drug: Fulvestrant
Drug: Pertuzumab
Drug: Trastuzumab

First Posted Date: 2022-10-12

Last Posted Date: 2024-02-26

Lead Sponsor: Fudan University

Target Recruit Count: 72

Registration Number: NCT05574881

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

Dalpiciclib Combined With Letrozole in Neoadjuvant Treatment of Stage Ⅱ-Ⅲ HR-positive/HER2-negative Breast Cancer

Phase 2

Conditions: Solid Tumor

Interventions: Drug: Dalpiciclib

First Posted Date: 2022-08-23

Last Posted Date: 2022-08-23

Lead Sponsor: Hebei Medical University Fourth Hospital

Target Recruit Count: 30

Registration Number: NCT05512780

mFOLFOX6 Combined With Dalpiciclib in Patients With Metastatic Colorectal Cancer

Phase 2

Recruiting

Conditions: Advanced/Metastatic Colorectal Cancer

Interventions: Drug: Dalpiciclib
Drug: Oxaliplatin injection
Drug: Calcium folinate
Drug: 5-fluorouracil

First Posted Date: 2022-07-29

Last Posted Date: 2023-02-28

Lead Sponsor: Sixth Affiliated Hospital, Sun Yat-sen University

Target Recruit Count: 18

Registration Number: NCT05480280

Locations: 🇨🇳
Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China

Mecapegfilgrastim for the Prevention of Dalpiciclib -Induced Neutropenia in Advanced Breast Cancer

Phase 2

Recruiting

Conditions: Metastatic Breast Cancer

Interventions: Drug: Mecapegfilgrastim
Drug: exemestane, fulvestrant, letrozole, tamoxifen
Drug: dalpiciclib

First Posted Date: 2022-07-19

Last Posted Date: 2023-04-12

Lead Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Target Recruit Count: 132

Registration Number: NCT05463601

Locations: 🇨🇳
中山大学中山纪念医院, Guangzhou, Guangdong, China

Pyrotinib, Dalpiciclib(SHR6390) and Endocrine Therapy in Subjects With Dual-receptor Positive(ER+/HER2+) Advanced Breast Cancer

Phase 1

Active, not recruiting

Conditions: Breast Cancer

Interventions: Drug: Dalpiciclib
Drug: Pyrotinib
Drug: Letrozole
Drug: Fulvestrant

First Posted Date: 2018-12-11

Last Posted Date: 2023-03-07

Lead Sponsor: Fudan University

Target Recruit Count: 59

Registration Number: NCT03772353

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy